ArticleOncogene2004
High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 151 citations in OpenAlex.
- Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.British journal of cancer · 2024Article
- Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro.The Journal of pathology · 2023Article
- Review
- Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker.Neoplasia (New York, N.Y.) · 2018Article
- Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer.Oncotarget · 2018Article
- Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer.Experimental & molecular medicine · 2017Article
- Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes.Oncotarget · 2016Article
- Altered expression of LINC-ROR in cancer cell lines and tissues.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis.Oncotarget · 2015Article
- The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.BMC genomics · 2015Article
- Molecular biology of bladder cancer.Hematology/oncology clinics of North America · 2015Review
- Expression of DDX27 contributes to colony-forming ability of gastric cancer cells and correlates with poor prognosis in gastric cancer.American journal of cancer research · 2015Article
- Mapping of the chromosomal amplification 1p21-22 in bladder cancer.BMC research notes · 2014Article
- Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma.Clinical epigenetics · 2014Article
- Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis.Cellular and molecular life sciences : CMLS · 2013Review
- Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA.Journal of translational medicine · 2013Article
- Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have screened 22 bladder tumour-derived cell lines and one normal urothelium-derived cell line for genome-wide copy number changes using array comparative genomic hybridization (CGH). Comparison of array CGH with existing multiplex-fluorescence in situ hybridization (M-FISH) results revealed excellent concordance. Regions of gain and loss were defined more accurately by array CGH, and several small regions of deletion were detected that were not identified by M-FISH. Numerous genetic changes were identified, many of which were compatible with previous results from conventional CGH and loss of heterozygosity analyses on bladder tumours. The most frequent changes involved complete or partial loss of 4q (83%) and gain of 20q (78%). Other frequent losses were of 18q (65%), 8p (65%), 2q (61%), 6q (61%), 3p (56%), 13q (56%), 4p (52%), 6p (52%), 10p (52%), 10q (52%) and 5p (43%). We have refined the localization of a region of deletion at 8p21.2-p21.3 to an interval of approximately 1 Mb. Five homozygous deletions of tumour suppressor genes were confirmed, and several potentially novel homozygous deletions were identified. In all, 15 high-level amplifications were detected, with a previously reported amplification at 6p22.3 being the most frequent. Real-time PCR analysis revealed a novel candidate gene with consistent overexpression in all cell lines with the 6p22.3 amplicon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.